Activating mutations in JAK1 and JAK2 have been described in patients with various hematological malignancies including acute lymphoblastic leukemia and myeloproliferative neoplasms, leading to clinical trials with JAK inhibitors.
While there has been a tremendous effort towards development of specific JAK inhibitors, mutations conferring resistance to such drugs have not been observed so far.
Taking advantage of a model of spontaneous cellular transformation, we sequenced JAK1 in selected tumorigenic BaF3 clones and identified 25 de novo JAK1 activating mutations, including 5 mutations already described in human leukemias. We further used this library of JAK1 mutation-positive cell lines to assess their sensitivity to ATP-competitive inhibitors.
While most JAK1 mutants were sensitive to ATP-competitive JAK inhibitors, mutations targeting Phe958 and Pro960 in the hinge region of the kinase domain rendered JAK1 constitutively active, but also resistant to all tested JAK inhibitors. Furthermore, mutation of the homologous Tyr931 in JAK2 wildtype or JAK2 V617F mutant found in patients with myeloproliferative neoplasms also conferred resistance to JAK inhibitors, such as the clinically used INCB018424.
Our data indicate that some activating mutations not only promote autonomous cell proliferation but also confer resistance to ATP-competitive inhibitors. In vivo, such a mutation can potentially occur as primary JAKactivating mutations but also as secondary mutations combining oncogenicity with drug resistance. The most common mechanism for constitutive activation and phosphorylation of STAT factors is the dysregulation of tyrosine kinases. In 2005, the identification of an activating mutation in JAK2 (the V617F mutation) as a STAT5-activating and disease-causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematological malignances (2) (3) (4) (5) . JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity, to mediate cytokine-induced signal transduction and activation of STAT transcription factors (6) . All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C-terminus flanked by a catalytically inactive pseudokinase domain with kinase-regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to membraneproximal region of the cytokine receptors (7, 8) . Soon after the JAK2 V617F discovery, we and others described that activating JAK1 mutations are relatively common in adult patients with T cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5 (9) (10) (11) . Several STAT5-activating JAK1 mutations were also reported in AML and breast cancer patients (10) .
Because of its central role in the pathophysiology of MPNs, the JAK2 V617F In our laboratory we previously described an in vitro model of spontaneous transformation of the IL-3-dependent hematopoietic BaF3 cell line towards growth factor-independent tumorigenic clones with constitutive STAT5 activation (14) . This model stemmed from the study of BaF3 cells transfected with an IL-9Rα mutant lacking the STAT-recruiting site (BaF3 phe116). This BaF3 phe116 almost completely fail to proliferate and activate STATs in response to IL-9 (15). However, upon prolonged culture with IL-9, a small number of cells manage to survive and even proliferate, allowing the selection of an IL-9-dependent cell line (BaF3 phe116/9) (14) . In contrast to parental BaF3 phe116 cells, those IL-9-selected cells could progress to autonomous cells (BaF3 Aut) after a second step of selection in the absence of cytokine.
These autonomous cells show a cytokine-independent activation of JAK1 and STAT5 and are highly tumorigenic when injected in mice, which is not the case for parental BaF3 phe116 and BaF3 phe116/9 (14, 16) . We previously showed that upregulation of the endogenous JAK1 gene was associated with the first step of transformation, namely increased sensitivity of BaF3 phe116 cells to IL-9 and promotion of the second step of transformation, namely progression towards cytokine-independent BaF3 autonomous cells (16) .
In this study, we show that 80% of the autonomous BaF3 clones, selected in our in vitro model, acquired activating point mutations in the kinase or pseudokinase domain of JAK1. These JAK1 mutations provide cells with tumorigenic potential by inducing constitutive activation of the JAK-STAT pathway, which supports their autonomous proliferation. We took advantage of this collection of JAK1 mutation-positive autonomous cell lines to study the sensitivity of different JAK1 mutations to JAK inhibitors. For the first time we report that mutations of the Phe958 and Pro960 do not only constitutively activate JAK1, but also render the mutated JAK1 protein resistant to ATPcompetitive inhibitors. The homologous mutation in JAK2, namely Y931C, also renders JAK2 wild-type or V617F mutant resistant to all tested ATPcompetitive inhibitors.
DESIGN AND METHODS

Cell culture and cytokines
BaF3 mouse hematopoietic pro-B cells were cultured in Dulbecco's modified Eagle's medium with fetal bovine serum (10%) and IL-3 (150 U/ml), which was produced by transfected CHO cells. Recombinant human IL-9 was produced in the baculovirus system and purified by affinity chromatography in our laboratory. The generation of BaF3 phe116 as well as BaF3 phe116/9 cells and the selection of autonomous cells was previously described (14) . The frequency of autonomous cells was assessed as previously described (14) .
IL-9-selected BaF3 phe116/9 and non-selected BaF3 phe116 cells were grown in the presence of IL-3, while autonomous clones were selected and subsequently amplified in the absence of IL-3. shown). Therefore, the numbering of mutated amino acids was based on the human JAK1 sequence, allowing to remain consistent with currently used nomenclature for JAK1 protein mutations in literature and to localize our JAK1 mutations in the previously described three-dimensional structure model of human JAK1 protein (9) .
Reverse transcription-quantitative PCR (RT-PCR)
Reverse transcription was performed as described above. Quantitative PCR reactions were performed using primers sets corresponding to murine JAK1 or murine Actin with qPCR™ Mastermix for SYBR Green I (Eurogentec). The sequences of primers (final concentration, 300 nM) were: mJAK1 5'-GGAGTGCAGTATCTCTCCTCTCT-3' (forward) and 5'-
To amplify corresponding cDNA PCR conditions were used as previously described (17, 18) . Results were analyzed by MyiQ software. Starting quantity of the transcripts was calculated using standard curves from a cDNA clone.
Plasmid construction, stable DNA transfections and analysis of transfected cells
All JAK1 and JAK2 mutants were generated using QuickChange XL II sitedirected mutagenesis kit (Stratagene) and subcloned into the pMX-GFP (for JAK1) or pMEGIX-GFP (for JAK2) biscistronic retroviral vector upstream of the IRES as previously described (17) (18) (19) . The mutated JAK1 and JAK2
constructs were verified by sequencing of the full-length JAK1 and JAK2 using DYEnamic ET Dye Terminator Kit (Amersham Biosciences). For stable transduction, typically, 0.5 x 10 6 BaF3 cells were infected by retroviruses produced by BOSC packaging cells using standardized protocol previously described (20) . Cells were subsequently sorted by FACS for equal level of GFP.
Western blots
For Western Blot analysis, 10 6 BaF3 cells were starved for 4 hours and lysed in 250 µl of Laemmli buffer (BioRad). We separed proteins using 12% pre- 
JAK1 structures
The three-dimensional structural model of the kinase and pseudokinase domain of JAK1 was previously described (9) 
Statistical analysis
Significant differences were determined using InStat software. The mean of two groups was compared with the students t-test. Normality tests were used to test the assumption of a normal distribution. Mean values ± SEM are shown. To better highlight the localization of mutated residues, we took advantage of the three-dimensional modeled structure of kinase (JH1) and pseudokinase (JH2) domain of JAK1 previously described (9) . As shown in Figure 1B , half of the affected residues (6 of 12 de novo mutations) of the pseudokinase domain (F635V, S646F, Y652H and V658I/L/F), including 3 mutations (S646F, Y652H
RESULTS
De novo mutations in kinase and
and V658F) that were previously identified in T-ALL patients (10, 11, 23) , are located within the pocket formed between the JH2 αC helix and an adjacent loop comprising Val658 and Tyr652 residues. These two regions of the JH2
domain were predicted to interact with the activation loop of the kinase domain in the active conformation (24) . The enrichment of this region in activating mutations suggests that this area represents a hotspot for mutations that might share a common mechanism to activate JAK1. Three of the JH1-located mutations (K1026E, Y1035C and S1043I) are also targeting the activation loop of the JH1 domain that is part of the interface between the kinase (JH1) and the pseudokinase (JH2) domain, further supporting this hypothesis.
For the mutations located in the JH1 kinase domain, we took advantage of the recently solved crystal structure of the JAK1 JH1 domain to detail their localization (21) . As shown in Figure 1C , D, E, from 13 JH1-located mutations, three (K1026E, Y1035C and S1043I) are located in the activation loop (Aloop), four mutations affect the same residue (F958V, F958C, F958S, F958L)
in the hinge region of the kinase domain at the entry of the ATP-binding pocket, three others (D895H, E897K and T901R) are located at the top of the kinase domain in the loop formed between two antiparallel β-strands (β2 and β3) and one mutation affects the loop formed between the β-strand-3 (β3) and the αC helix of the JH1 domain (L910Q). Altogether, beside the mutations targeting the JH1/JH2 interface, the other activating mutations found in this study point to two other hotspots for the regulation of JAK enzymatic activity:
the hinge region and in the loop formed between β2-and β3-strand in the kinase domain. Moreover, structural modeling of these hotspots also suggests that each of them might have a distinct molecular mechanism for kinase activation (25) .
JAK1 mutations spontaneously occurring in autonomous BaF3 cells are JAK-STAT pathway activating mutations
We previously showed that progression of BaF3 phe116/9 cells toward cytokine-independence was associated with constitutive activation of JAK1 and STAT5 (14) . We therefore examined whether all JAK1-mutated autonomous clones (BaF3 Aut) showed a similar signaling profile. We chose One of the main mechanisms of secondary resistance in patients treated with tyrosine kinase inhibitors is acquisition of new inhibitor-resistant mutations.
The JAK1 V658F mutation is constitutive active (26) and has been described in ALL and AML patients (10, 11), making it a good candidate for JAK inhibitor therapy. We wondered if the acquisition of a secondary, JAK inhibitor resistant mutation in the kinase domain, would render JAK1 V658F insensitive to JAK inhibition. We therefore transduced parental BaF3 cells with the V658F (JAK inhibitor sensitive), F958C (JAK inhibitor resistant) and the V658F/F958C double JAK1 mutants and selected these cells for autonomous proliferation.
After that, we measured the proliferation of these cells with increasing concentration of INCB018424 and calculated the IC50 ( Figure 4B ). As expected, BaF3 cells expressing the F958C mutant were less sensitive than BaF3 V658F, while the level of JAK1 mutant expression was identical ( Figure   4C ). Importantly, cells expressing the double mutants V658F/F958C showed identical sensitivity to the inhibitor as cells expressing F958C mutant alone ( Figure 4B ). These results show that acquisition of a JAK inhibitor resistant mutation such as the F958C in cells dependent on activated JAK1 for growth is a potential mechanism of the secondary resistance to JAK inhibitor therapy.
Long-term culture of F958V-positive BaF3 cells with JAK inhibitor leads to increased expression of F958V JAK1 that correlates with increased resistance to JAK inhibitor
We demonstrated that the F958V JAK1 mutation renders BaF3 cells resistant 
JAK2 Y931C, the homologous mutation of JAK1 F958C, confers resistance to JAK inhibitors
Because of its central role in the pathophysiology of MPNs, the JAK2 V617F
is an attractive therapeutic target (8) . Currently several JAK2 inhibitors are under development or/and clinical trials for MPNs (27) . Identification of JAK inhibitor-resistant mutations in JAK2 is thus of great importance. We therefore introduced the Y931C, a homologous mutation of JAK1 F958C, into WT or V617F JAK2 protein and selected these cells for autonomous proliferation.
As shown in Figure 6A , all three JAK2 mutants, but not JAK2 WT or control 
DISCUSSION
The acquisition of growth signal self-sufficiency is one of the hallmarks of cancer (28) . In this paper we show that a broad spectrum of spontaneous mutations in one of the endogenous JAK1 alleles is the main mechanism that confers to BaF3 cells cytokine-independent growth capability in vitro and full tumorigenicity in vivo (Supplemental 
